Using nanomedicine to improve treatment for pancreatic cancer
Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer
This study is looking at a new way to treat pancreatic cancer by using a combination of a chemotherapy drug and a special treatment that helps deliver the medicine better to the tumor, which could lead to improved results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11006253 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for pancreatic cancer by combining the chemotherapy drug gemcitabine with a dual inhibitor called ONC201. The study aims to enhance drug delivery to the tumor site by reducing the surrounding fibrous tissue, which often hinders effective treatment. By targeting specific cancer pathways and using advanced drug delivery methods, the research seeks to improve the effectiveness of existing therapies for patients with pancreatic cancer. Patients may benefit from a more effective treatment regimen that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those with specific KRAS mutations.
Not a fit: Patients with non-pancreatic cancers or those who do not have KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using similar dual inhibition strategies for cancer treatment, indicating potential for success in this approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Mahato, Ram I. — University of Nebraska Medical Center
- Study coordinator: Mahato, Ram I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.